Kalaris Therapeutics Inc (KLRS) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Kalaris Therapeutics Inc

    NASDAQ: KLRS · Real-Time Price · USD
    6.64
    -0.45 (-6.35%)
    At close: Oct 03, 2025, 3:59 PM
    6.77
    1.96%
    After-hours: Oct 03, 2025, 04:22 PM EDT

    Kalaris Therapeutics Inc Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year Q1 2025 Q2 2024 Q1 2024 Q4 2023
    Period Ending Mar 31, 2025 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023
    Net Income
    		 -22.72M -12.53M -6.88M -3.47M
    Depreciation & Amortization
    		 n/a n/a n/a n/a
    Stock-Based Compensation
    		 758K 384K 62K 31K
    Other Working Capital
    		 -313K -1.73M -2.15M -1.31M
    Other Non-Cash Items
    		 2.6M 2.56M 1.04M 105K
    Deferred Income Tax
    		 n/a n/a n/a n/a
    Change in Working Capital
    		 -703K -3.05M -2.88M -801K
    Operating Cash Flow
    		 -20.07M -12.63M -8.66M -4.14M
    Capital Expenditures
    		 n/a n/a n/a n/a
    Cash Acquisitions
    		 n/a n/a n/a n/a
    Purchase of Investments
    		 n/a n/a n/a n/a
    Sales Maturities Of Investments
    		 n/a n/a n/a n/a
    Other Investing Acitivies
    		 n/a n/a n/a n/a
    Investing Cash Flow
    		 n/a n/a n/a n/a
    Debt Repayment
    		 17.49M 9.99M 4.99M n/a
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 99.86M 95K 112K 117K
    Financial Cash Flow
    		 125.69M 18.42M 13.44M 6.86M
    Net Cash Flow
    		 105.62M 5.79M 4.78M 2.72M
    Free Cash Flow
    		 -20.07M -12.63M -8.66M -4.14M

    Add to Watchlist